Losartan Potassium
Product Images NDC 60760-645

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 60760-645). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

645 (Losartan 645 30)

Losartan Potassium 50mg tablets label shows quantity 30, manufactured by Zhejiang Huahai Pharmaceutical Co., Ltd., China, and packaged by St. Mary's Medical Park Pharmacy, Oro Valley, AZ. The label includes NDC 60760-645-30 and instructions to store at controlled room temperature 15°-30°C (59°-86°F).*

FDA Label Image

Chemical Structure (Spl Image1 Structure1)

Chemical structure of losartan potassium showing its molecular arrangement including a chlorophenyl group and a potassium ion (K+).*

FDA Label Image

Figure 1 (Spl Image2 Figure1)

A line graph comparing the percentage of patients with the primary endpoint over a 66-month study period between Atenolol and Losartan Potassium. Atenolol is represented by a dotted line, and Losartan Potassium by a solid line. The graph notes an adjusted risk reduction of 13% with a p-value of 0.021.*

FDA Label Image

Figure 2 (Spl Image3 Figure2)

A line chart comparing the percentage of patients with fatal or non-fatal stroke over study months up to 66 months for Atenolol and Losartan Potassium. Losartan Potassium shows a lower percentage increase than Atenolol, with an adjusted risk reduction of 25% and a p-value of 0.001.*

FDA Label Image

Figure 3 (Spl Image4 Figure3)

A forest plot chart titled 'Primary Endpoint Events within Demographic Subgroups' comparing event rates of Losartan Potassium versus Atenolol. The chart shows hazard ratios with 95% confidence intervals for primary composite events and stroke outcomes across various demographic subgroups including age, gender, race, ISH, diabetes, and history of cardiovascular disease. Symbols represent sample sizes and indicate risk favoring either Losartan Potassium or Atenolol.*

FDA Label Image

Figure 4 (Spl Image5 Figure4)

A line chart comparing the percentage of patients with an event over 48 months for Losartan Potassium versus placebo. The solid line represents Losartan Potassium, while the dotted line represents placebo. Text indicates a risk reduction of 16.1% with a p-value of 0.022.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.